Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Axicabtagene Ciloleucel in Relapsed or Refractory HIV-Associated Aggressive B-Cell Non-Hodgkin Lymphoma

NCT05077527 is registered in ClinicalTrials.gov with AIDS Malignancy Consortium as lead sponsor.

NCT NCT05077527
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05077527 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Axicabtagene Ciloleucel in Relapsed or Refractory HIV-Associated Aggressive B-Cell Non-Hodgkin Lymphoma
Lead sponsor
AIDS Malignancy Consortium
Phase
Phase 1
Overall status
Recruiting
Start date
February 13, 2025
Completion date
January 31, 2029
Enrollment
20 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

aids-related diffuse large b-cell lymphoma, aids-related non-hodgkin lymphoma, hiv infection, recurrent diffuse large b-cell lymphoma, recurrent grade 3b follicular lymphoma, recurrent high grade b-cell lymphoma, recurrent non-hodgkin lymphoma, recurrent primary mediastinal (thymic) large b-cell lymphoma, recurrent transformed b-cell non-hodgkin lymphoma, refractory diffuse large b-cell lymphoma, refractory grade 3b follicular lymphoma, refractory high grade b-cell lymphoma, refractory non-hodgkin lymphoma, refractory primary mediastinal (thymic) large b-cell lymphoma, refractory transformed b-cell non-hodgkin lymphoma